This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...

Chimeric antigen receptor (CAR) T-cell therapy is one of oncology's most powerful ideas: Harvest a cancer patient's own ...

CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...

Scientists have developed a way to turn the body's own immune cells into cancer-fighting agents—without removing them from ...

When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Expanding CAR T beyond academic centers is primarily an access imperative, as travel distance and authorized-site ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...